Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Federico II University
To better understand the direct effects of paricalcitol on anemia in patients with chronic kidney disease (stage 3-5), we conducted a pilot trial in 60 patients who were randomly allocated equally to 2 groups to receive or not paricalcitol orally for 6 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age \> 18
written informed consent
CKD stage 3-5 (eGFR \<60 ml/min/1,73 m2)
PTH 30-300 pg/ml
Hb \<10 g/dl \>3 consecutive months
Ferritin \> 100 ng/ml
transferrin saturation (TSAT) 20-40%
mean corpuscular volume (MCV) 85-95%
for patients treated with Ace-inhibitors or angiotensin receptor blockers, dose stable \>3 months
for patients treated with erythropoiesis-stimulating agents (ESA), dose stable \>3 months
You may not be if
anemia due to non renal cause
presence of malignancies, inflammatory or infectious disease \>3 months
pregnancy
bleeding \>6 months
C-reactive protein (CRP) \>1 mg/dl
poorly controlled hypertension (PAS \> 170 mmHG and PAD \>100 mmHg)
severe malnutrition
hypercalcemia (\>10,5 mg/dl)
hyperphosphatemia (\>5,5 mg/dl)
surgical interventions \>3 months
acute myocardial infarction, unstable angina, stroke or transitory ischemic attack, deep venous or pulmonary thromboembolism, congestive heart failure \>3 months
Clareo Health | Paricalcitol Effect on Anemia in CKD
